Information between 14th July 2024 - 12th September 2024
Note: This sample does not contain the most recent 2 weeks of information. Up to date samples can only be viewed by Subscribers.
Click here to view Subscription options.
Parliamentary Debates |
---|
Healthcare Provision: East of England
43 speeches (13,792 words) Tuesday 3rd September 2024 - Westminster Hall Department of Health and Social Care Mentions: 1: Sarah Owen (Lab - Luton North) Something that is very close to my heart when it comes to cancer care is brain tumours. - Link to Speech |
Oral Answers to Questions
136 speeches (10,560 words) Tuesday 23rd July 2024 - Commons Chamber Department of Health and Social Care Mentions: 1: Simon Hoare (Con - North Dorset) Nearly 10 children a month die from brain tumours, and I know that the public health Minister takes this - Link to Speech |
Written Answers |
---|
Brain: Tumours
Asked by: Alistair Strathern (Labour - Hitchin) Tuesday 10th September 2024 Question to the Department of Health and Social Care: To ask the Secretary of State for Health and Social Care, whether he plans to improve access to clinical trials for those affected by brain tumours. Answered by Andrew Gwynne - Parliamentary Under-Secretary (Department of Health and Social Care) The Department is committed to implementing the recommendations of Lord O'Shaughnessy’s review into commercial clinical trials, making sure that the United Kingdom leads the world in clinical trials, and ensuring that innovative, lifesaving treatments are accessible to National Health Service patients, including those with brain tumours. The Department funded National Institute of Health and Care Research (NIHR) funds research and research infrastructure, which supports patients and the public to participate in high-quality research. In addition, the NIHR provides an online service called Be Part of Research, which promotes participation in health and social care research by allowing users to search for relevant studies and register their interest. This makes it easier for people to find and take part in health and care research that is relevant to them. When designing research studies, researchers consider inclusion and exclusion criteria carefully to ensure they are not unnecessarily excluding specific groups who would benefit from the outcome of their study. The Health Research Authority is developing guidance to improve practices in this area. |
Brain Cancer: Medical Treatments
Asked by: Claire Hazelgrove (Labour - Filton and Bradley Stoke) Monday 9th September 2024 Question to the Department of Health and Social Care: To ask the Secretary of State for Health and Social Care, what steps his Department is taking to (a) widen treatment options on the NHS for people with brain tumours and (b) prevent patients from having to go abroad to access treatment. Answered by Karin Smyth - Minister of State (Department of Health and Social Care) People with brain tumours have access to various treatment options on the National Health Service, including surgery, radiotherapy and systematic anti-cancer therapies, depending on the nature and stage of the tumour. The Government is committed to improving waiting times for cancer treatment, so that people with brain tumours can get access to the care they need more quickly. We will start by delivering an extra 40,000 operations, scans, and appointments each week, as the first step to ensuring early diagnosis and faster treatment. Lord Darzi is currently undertaking an independent investigation into the state of the NHS, the findings of which will feed into the Government’s 10-year plan to build a health service that is fit for the future. |
Arms Length Bodies Publications |
---|
Sep. 11 2024
NICE Source Page: Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement Publication Type: Supporting evidence Document: Committee papers (PDF 6.5 MB) (webpage) Published Found: tumours and brain metastases. |
Aug. 08 2024
NICE Source Page: Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement Publication Type: Final draft guidance Document: Committee papers (PDF 6.5 MB) (webpage) Published Found: tumours and brain metastases. |
Jul. 30 2024
NICE Source Page: Maternal and child nutrition Publication Type: Draft guidance consultation Document: Committee member list: DOI PDF 927 KB (webpage) In consultation Found: Direct, non- financial professional and personal Author for Cochrane Reviews in the management of brain |
Jul. 30 2024
NICE Source Page: Maternal and child nutrition Publication Type: Declaration of interests Document: Register of interests PDF 927 KB (webpage) In consultation Found: Direct, non- financial professional and personal Author for Cochrane Reviews in the management of brain |
Jul. 09 2024
NHS England Source Page: 2022/23 National Cost Collection Data Publication Document: The National Schedule of NHS Costs 2022/23 (Excel) Data and statistics Found: Brain Tumours with length of stay 1 day or more, with CC Score 0Acute7084723.791210.343DCDaycasePM43APaediatric |
May. 29 2024
NICE Source Page: Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over Publication Type: Summary PDF Document: Download (PDF) (webpage) Published Found: Informa tion and suppor t The NHS w ebpage on brain tumours may be a good place t o find out mor e. |
Apr. 27 2022
NICE Source Page: Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies Publication Type: Summary PDF Document: Download guidance (PDF) (webpage) Published Found: metastases can be tr eated wit h stereotactic radiosur gery or radiot herap y (see NICE's guideline on brain |
May. 13 2020
NICE Source Page: Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer Publication Type: Summary PDF Document: Download guidance (PDF) (webpage) Published Found: Lorlatinib's ability t o reach t he brain means t hat patient s whose brain tumours r espond t o treatment |
Jul. 23 2014
NICE Source Page: Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen Publication Type: Summary PDF Document: Download guidance (PDF) (webpage) Published Found: seizur es or ot her pr edisposing f actors f or seizur es, such as underlying brain injur y, stroke, brain |
Feb. 27 2008
NICE Source Page: Structural neuroimaging in first-episode psychosis Publication Type: Summary PDF Document: Download guidance (PDF) (webpage) Published Found: The Assessment Gr oup estimat ed test accuracy rat es for det ecting brain tumours or cyst s to be |
Jun. 27 2007
NICE Source Page: Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma Publication Type: Summary PDF Document: Download guidance (PDF) (webpage) Published Found: Grade 4 gliomas ar e usually GBM. 2.2 Brain tumours account f or fewer than 2% of all primar y cancers |
Apr. 26 2001
NICE Source Page: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer) Publication Type: Summary PDF Document: Download guidance (PDF) (webpage) Published Found: t erms-and- conditions#notice-of -right s).Page 4 of 282 Clinic al Need and Pr actice 2.1 Although brain |
NICE Source Page: Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over TS ID 11974 Document: 28716-Vorasidenib-for-Glioma-V1.0-DEC2023-NON-CONF.pdf (nihr.ac.uk) (PDF) Awaiting development Found: They represent 50% to 60% of all primary brain tumours, and about 0.8% of all malignant neoplasms in |